Item 8.01. Other Events.

As previously disclosed by Hoth Therapeutics, Inc. (the "Company") on a Current Report on Form 8-K filed with the Securities and Exchange Commission on August 5, 2020, the Company entered into a Sublicense Agreement (the "Agreement") with Isoprene Pharmaceutics, Inc. ("Isoprene") pursuant to the Commercial Evaluation Sublicense and Option Agreement by and among the Company, the University of Maryland, Baltimore and Isoprene dated March 8, 2019. Pursuant to the terms of the Agreement, on September 10, 2020, the Company entered into a note purchase agreement with Isoprene pursuant to which it loaned Isoprene $50,000 evidenced by a convertible promissory note issued by Isoprene in favor of the Company.


                                       1

© Edgar Online, source Glimpses